A Native LH1-RC-HiPIP Supercomplex from an Extremophilic Phototroph.

Halorhodospira (Hlr.) halophila strain BN9622 is an extremely halophilic and alkaliphilic purple phototrophic bacterium and has been widely used as a model for exploring the osmoadaptive and photosynthetic strategies employed by phototrophic extreme halophiles that enable them to thrive in hypersaline environments. Here we present the cryo-EM structures of (1) a unique native Hlr.

The Thermal-Stable LH1-RC Complex of a Hot Spring Purple Bacterium Powers Photosynthesis with Extremely Low-Energy Near-Infrared Light.

is a hot spring purple nonsulfur phototrophic bacterium that contains bacteriochlorophyll (BChl) . Here, we present a 2.21 Å cryo-EM structure of the thermostable light-harvesting 1-reaction center (LH1-RC) complex from .

Multicomponent Self-Assembly and Self-Sorting of Polymer Micelles in Water: Selective and Switchable Association by Kinetic or Thermodynamic Control.

Herein, we report multicomponent self-assembly and self-sorting of polymer micelles in water using mixtures of an anionic random copolymer bearing sodium sulfonate and dodecyl groups and random copolymers carrying poly(ethylene glycol) (PEG) and alkyl groups. In pure water, the anionic copolymer is co-self-assembled with the PEG copolymers to form anion/PEG-fused micelles with a controlled aggregation number. By designing the composition or alkyl groups of PEG copolymers, the fused micelle is reversibly self-sorted into discrete anion or PEG micelles in the presence of NaCl.

Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy.

Although carboplatin (CBDCA) is classified as a moderately emetogenic agent, the majority of guidelines recommend the use of a neurokinin-1 receptor antagonist in addition to a 5-hydroxytryptamine type 3 receptor antagonist with dexamethasone (DEX) for CBDCA-containing chemotherapy because of its higher emetogenic risk. However, the additional efficacy of aprepitant (APR) in CBDCA-containing treatment remains controversial, and data on multiple-day treatments are limited. Etoposide (ETP) was administered on days 1-3 in the CBDCA + ETP regimen, and it is important to evaluate suitable antiemetic therapy for the regimen.